Despite the pandemic, Novo Nordisk finished 2020 on a high and reported a healthy operating performance. This was a function of the sustained uptake for GLP-1, despite varying (and persistent) issues elsewhere. Management stuck to its extravagant shareholder reward programme.
However, it is high time that newer non-diabetes growth drivers are identified and pursued. Luckily, the group has the balance-sheet cushion to pursue big growth ambitions. Until new growth avenues are identified, sadly, t ....
05 Feb 2021
Strong end to 2020, but search beyond diabetes is still on
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong end to 2020, but search beyond diabetes is still on
Novo Nordisk A/S Class B (NOVO.B:CSE) | 0 0 0.0%
- Published:
05 Feb 2021 -
Author:
Amandeep Goyal -
Pages:
5
Despite the pandemic, Novo Nordisk finished 2020 on a high and reported a healthy operating performance. This was a function of the sustained uptake for GLP-1, despite varying (and persistent) issues elsewhere. Management stuck to its extravagant shareholder reward programme.
However, it is high time that newer non-diabetes growth drivers are identified and pursued. Luckily, the group has the balance-sheet cushion to pursue big growth ambitions. Until new growth avenues are identified, sadly, t ....